NCT05309421Pembrolizumabadvanced melanomastage III/IV unresectable melanoma
…on with Pembrolizumab in a phase 2 trial in advanced melanoma ( NCT05309421), with 80% of the vaccine targets eliciting T-cell responses an…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT05309421 ×
NCT05309421
This institution is selected. Its supporting articles are shown below.